<DOC>
	<DOCNO>NCT00755950</DOCNO>
	<brief_summary>The purpose study ass whether two high dos ( 280mg 420mg three time daily ) silymarin therapy safe tolerable , shorten illness patient acute viral hepatitis compare placebo .</brief_summary>
	<brief_title>Randomized Placebo-controlled Trial Evaluating Safety Efficacy Silymarin Treatment Patients With Acute Viral Hepatitis</brief_title>
	<detailed_description>Currently , acute viral hepatitis ( AVH ) management base diet rest silymarin remain among popular herb use treat viral hepatitis U.S. abroad . Although numerous randomized clinical trial conduct assess efficacy silymarin chronic hepatitis C , study do assess efficacy silymarin acute viral hepatitis . Among , efficacy silymarin establish . This could attribute small number study conduct , small sample size , high drop rate , low dos silymarin use . Therefore , justified evaluate silymarin safety efficacy use high dos previously study AVH . Primary safety objective : - To assess safety tolerability two silymarin dos patient AVH determine number percentage subject develop Adverse Events group elicit questionnaire administer specific visit hematology , blood chemistry physical examination . Primary efficacy objective : - To assess percentage subject normalize total direct bilirubin group . Secondary Objective : To assess percentage subject group : - Normalize liver enzyme , i.e . alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) inflammatory reactant , i.e . erythrocyte sedimentation rate ( ESR ) C-reactive protein ( CRP ) . - Resolve clinical symptom AVH return baseline activity level quality life ( QOL ) assess physical examination use previously evaluate Arabic-translated SF-36 form adapt use patient liver disease . To assess : - Differences silymarin response different AVH etiology ( i.e . HAV , HBV , HCV , HEV ) use subgroup analysis . To compare : - Progression acute chronic HCV infection subject HCV-caused acute AVH .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Diagnosis acute viral hepatitis ( &lt; 1 month ) manifest combination follow symptom : jaundice , darkcolored urine , lightcolored stool , pruritus , pruritic red hive , fever , nausea , vomit , anorexia , aversion smoking right upper abdominal discomfort , pain feeling pressure . Serum ALT level &gt; 2.5 time upper limit normal . Albumin level &gt; 3.5 gm/dl Negative antiHCV antibody Males females &gt; = 18 year age . Subject give write informed consent . If patient 18 21 year parents/legal guardian have/has also sign informed consent form . The subject able willing undertake studyrequired procedure ability take oral medication . Subjects &lt; 18 year age Pregnant breastfeed woman Suspected hypersensitivity silymarin multivitamin Advanced liver disease ( e.g . ascites , bleed esophageal varix hepatic encephalopathy ) Chronic liver disease cirrhosis Subjects positive antiHCV antibody Simultaneous elevation bilirubin &gt; 10 mg/dl along ALT level 100 150 U/L Platelets count &lt; 150,000 Subjects morbid obesity i.e . Body Mass Index ( BMI ) &gt; 40 Subjects severe illness , e.g. , multisystem failure , cancer poorly control diabetes i.e . know diabetic Hemoglobin A1C ( HbA1C ) &gt; 7 % Obvious history druginduced acute hepatitis . A careful history medication , pesticide hepatotoxic exposure occur within one month prior symptom onset take . If patient unaware name drug , ( ) ask bring inspection . Current use Silymarin recent use within past two week . Other condition , opinion investigator , make patient unsuitable enrollment could interfere his/her participation , completion , protocol ( e.g . severe mental illness ) The subject currently participate clinical trial ( marketed product otherwise ) , do within 30 day 5 halflives ( whichever longer ) prior screen visit History current drug alcohol abuse Female patient childbearing potential without negative pregnancy test Patient know HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Acute</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Silymarin</keyword>
	<keyword>Global Health</keyword>
</DOC>